Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$6.77 +1.7%	$6.79	$5.47 ▼ $14.38	$556.12M	0.86	437,755 shs	2.03 million shs
EMBC Embecta	$9.64 +3.9%	$11.04	$9.20 ▼ $21.48	$563.39M	1.13	491,521 shs	1.09 million shs
IRMD iRadimed	$60.84 +0.2%	$55.57	$42.34 ▼ $63.29	$773.58M	0.92	43,590 shs	188,754 shs
LNSR LENSAR	$12.76 +1.7%	$13.43	$3.50 ▼ $17.31	$150.47M	0.52	90,721 shs	1.33 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	0.00%	+3.36%	+3.20%	-25.03%	+20.89%
EMBC Embecta	0.00%	-1.33%	-7.75%	-21.50%	-21.43%
IRMD iRadimed	0.00%	+4.46%	+4.64%	+16.08%	+41.32%
LNSR LENSAR	0.00%	+2.82%	-7.00%	-9.70%	+190.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	3.3461 of 5 stars	3.3	0.0	0.0	0.0	2.3	4.2	1.3
EMBC Embecta	4.4137 of 5 stars	3.2	1.0	3.3	0.0	1.9	3.3	3.8
IRMD iRadimed	4.6971 of 5 stars	2.5	2.0	2.5	4.4	3.2	3.3	1.9
LNSR LENSAR	1.2903 of 5 stars	2.0	3.0	0.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.67	Moderate Buy	$14.33	111.72% Upside
EMBC Embecta	2.33	Hold	$19.33	100.55% Upside
IRMD iRadimed	3.00	Buy	$72.00	18.34% Upside
LNSR LENSAR	2.00	Hold	$15.00	17.55% Upside

Current Analyst Ratings Breakdown

Latest LNSR, IRMD, EMBC, and BVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	EMBC Embecta	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00
5/23/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	BVS Bioventus	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$15.00
4/10/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$15.00
4/9/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$567.70M	0.98	$0.54 per share	12.58	$2.80 per share	2.42
EMBC Embecta	$1.12B	0.50	$3.34 per share	2.89	($12.80) per share	-0.75
IRMD iRadimed	$73.24M	10.57	$1.58 per share	38.45	$6.85 per share	8.88
LNSR LENSAR	$53.49M	2.81	N/A	N/A	$0.42 per share	30.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	-$0.48	N/A	14.72	N/A	-7.11%	15.61%	4.01%	N/A
EMBC Embecta	$78.30M	$0.90	10.71	3.14	0.61	4.89%	-19.67%	12.27%	8/8/2025 (Estimated)
IRMD iRadimed	$19.23M	$1.55	39.25	30.42	N/A	26.33%	23.28%	20.59%	7/30/2025 (Estimated)
LNSR LENSAR	-$31.40M	-$4.85	N/A	∞	N/A	-99.17%	-737.30%	-81.69%	8/6/2025 (Estimated)

Latest LNSR, IRMD, EMBC, and BVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2025	Q2 2025	EMBC Embecta	$0.66	$0.70	+$0.04	$0.40	$261.77 million	$259.00 million
5/8/2025	Q1 2025	LNSR LENSAR	-$0.1550	-$2.32	-$2.1650	-$2.32	$13.40 million	$11.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	6.22%	N/A	66.67%	N/A
IRMD iRadimed	$0.68	1.12%	N/A	43.87%	1 Years
LNSR LENSAR	N/A	N/A	N/A	N/A	N/A

Latest LNSR, IRMD, EMBC, and BVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/5/2025	EMBC Embecta	quarterly	$0.15	4.51%	5/28/2025	5/28/2025	6/13/2025
5/5/2025	IRMD iRadimed	quarterly	$0.17	1.3%	5/20/2025	5/20/2025	5/30/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
EMBC Embecta	N/A	2.48	1.83
IRMD iRadimed	N/A	8.87	7.62
LNSR LENSAR	N/A	1.81	1.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
EMBC Embecta	93.83%
IRMD iRadimed	92.34%
LNSR LENSAR	40.15%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
EMBC Embecta	0.42%
IRMD iRadimed	36.80%
LNSR LENSAR	38.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.14 million	54.46 million	Not Optionable
EMBC Embecta	2,100	58.44 million	58.20 million	Optionable
IRMD iRadimed	110	12.72 million	8.04 million	Optionable
LNSR LENSAR	110	11.79 million	7.25 million	Optionable

LNSR, IRMD, EMBC, and BVS Headlines

Recent News About These Companies

LENSAR (NASDAQ:LNSR) Stock Price Up 2% - Here's What Happened

June 25, 2025 | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders

June 11, 2025 | morningstar.comM

$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to Act

June 10, 2025 | morningstar.comM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders

June 5, 2025 | morningstar.comM

LENSAR, Inc. Grants 3,090 Restricted Stock Units to New Employees as Inducement for Employment

June 4, 2025 | nasdaq.com

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Is Investigating the Merger: SSBK, LNSR, iCAD and BSGM

June 3, 2025 | morningstar.comM

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

June 3, 2025 | businesswire.com

Short Interest in LENSAR, Inc. (NASDAQ:LNSR) Decreases By 27.0%

June 2, 2025 | marketbeat.com

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

LENSAR Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025 | globenewswire.com

Is LENSAR (LNSR) a Deeply Undervalued Stock?

April 10, 2025 | msn.com

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

March 26, 2025 | businesswire.com

Lensar downgraded to Hold from Buy at Lake Street

March 26, 2025 | markets.businessinsider.com

ALC Stock Rises Following the Merger Agreement With LENSAR

March 25, 2025 | zacks.com

Lake Street Downgrades LENSAR (LNSR)

March 25, 2025 | msn.com

Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders

March 24, 2025 | tmcnet.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating LENSAR, Inc. Buyout

March 24, 2025 | markets.businessinsider.com

Lake Street Reaffirms Their Buy Rating on LENSAR (LNSR)

March 24, 2025 | markets.businessinsider.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR

March 24, 2025 | prnewswire.com

LNSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LENSAR, Inc. Is Fair to Shareholders

March 24, 2025 | businesswire.com

LENSAR - Top Healthcare Equipment Stock

March 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR, IRMD, EMBC, and BVS Company Descriptions

Bioventus NYSE:BVS

$6.77 +0.11 (+1.65%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.76 -0.01 (-0.15%)

As of 06/27/2025 05:54 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Embecta NASDAQ:EMBC

$9.64 +0.36 (+3.88%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.64 0.00 (-0.01%)

As of 06/27/2025 04:35 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

iRadimed NASDAQ:IRMD

$60.84 +0.13 (+0.21%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$60.82 -0.02 (-0.02%)

As of 06/27/2025 05:18 PM Eastern

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

LENSAR NASDAQ:LNSR

$12.76 +0.21 (+1.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.76 0.00 (0.00%)

As of 06/27/2025 05:50 PM Eastern

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time